A5059451077- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Monoclonal and Polyclonal Antibodies Research
- Acute Lymphoblastic Leukemia research
- Advanced Breast Cancer Therapies
- Glycosylation and Glycoproteins Research
- Chronic Myeloid Leukemia Treatments
- Phagocytosis and Immune Regulation
- Complement system in diseases
- Gastrointestinal Tumor Research and Treatment
- Genomic variations and chromosomal abnormalities
- PI3K/AKT/mTOR signaling in cancer
- Immune Cell Function and Interaction
- Renal Diseases and Glomerulopathies
- Viral-associated cancers and disorders
- Blood groups and transfusion
- Immunotherapy and Immune Responses
- Multiple Myeloma Research and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Tea Polyphenols and Effects
- Childhood Cancer Survivors' Quality of Life
- CAR-T cell therapy research
- Multiple and Secondary Primary Cancers
- Cancer Immunotherapy and Biomarkers
University of Rochester Medical Center
2016-2025
University of Rochester
2014-2023
Cancer Institute (WIA)
2017
Mayo Clinic
2006-2015
Cornell University
2015
WinnMed
2004-2015
Mayo Clinic in Arizona
2005-2014
University of Minnesota Rochester
2012
Palmetto Hematology Oncology
2000-2011
The Ohio State University
2009
Clinical trials that led to ibrutinib's approval for the treatment of chronic lymphocytic leukemia showed its side effects differ from those traditional chemotherapy. Reasons discontinuation in clinical practice have not been adequately studied. We conducted a retrospective analysis patients treated with ibrutinib either commercially or on trials. aimed compare type and frequency toxicities reported setting, assess rates, evaluate outcomes. This multicenter, included ibrutinib-treated at...
Summary Nearly all information about patients with chronic lymphocytic leukaemia ( CLL ) who develop diffuse large B ‐cell lymphoma [ R ichter syndrome RS )] is derived from retrospective case series or treated on clinical trials. We used the M ayo C linic Database to identify newly diagnosed between J anuary 2000 and uly 2011. Individuals developed biopsy‐proven during follow‐up were identified. After a median of 4 years, 37/1641 (2·3%) . The rate was approximately 0·5%/year. Risk...
Retrospective studies suggest cytogenetic abnormalities detected by interphase fluorescent in situ hybridization (FISH) can identify patients with chronic lymphocytic leukemia (CLL) who will experience a more aggressive disease course. Other that may acquire chromosome during the course of their disease. There are minimal prospective data on clinical utility widely used hierarchical FISH prognostic categories newly diagnosed early-stage CLL or frequency clonal evolution as determined...
Little is known about the spectrum or frequency of comorbidities in patients with chronic lymphocytic leukemia (CLL). We investigated prevalence and prognostic implications newly diagnosed CLL. Local/non-referred CLL evaluated by a hematologist at Mayo Clinic within 1 year diagnosis were eligible for this retrospective review. Of 1195 individuals newly-diagnosed between 1995 2006, 373 (31%) local/non-referred. At diagnosis, 89% these had one more comorbidities, 46% least major comorbidity....
To define the optimal dose of Polyphenon E for chronic daily administration and tolerability in patients with lymphocytic leukemia (CLL).
The prevalence of chronic lymphocytic leukemia (CLL) increases with age. Although chemoimmunotherapy (CIT) has dramatically improved response rates in patients CLL, some CIT regimens are not well tolerated by many >or=70 years age.Sixty-four previously untreated CLL and serum creatinine <1.5 times the upper limit normal who met National Cancer Institute (NCI) 96-WG criteria for treatment received pentostatin (2 mg/m(2)), cyclophosphamide (600 rituximab (375 mg/m(2)). authors measured...
Summary In vitro studies have demonstrated that surface expression of CD49d on chronic lymphocytic leukaemia (CLL) B cells facilitates leukaemic cell–stromal interactions by binding to fibronectin. This interaction reduces both spontaneous and drug‐induced apoptosis. The present study measured flow cytometry in a cohort untreated CLL patients previously accrued prospective observational evaluated the relationship with overall survival (OS). Among 158 tested, percentage expressing ranged from...
Abstract BACKGROUND: The objective of the current study was to follow up results phase 1 testing by evaluating clinical efficacy green tea extract Polyphenon E for patients with early stage chronic lymphocytic leukemia (CLL). METHODS: Previously untreated asymptomatic, Rai 0 II CLL and an absolute lymphocyte count (ALC) ≥ 10 × 9 /L were eligible this 2 trial. a standardized dose epigallocatechin gallate (EGCG) (2000 mg per dose) administered twice daily. RESULTS: A total 42 received at 2000...
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted multicenter retrospective cohort analysis of patients treated venetoclax to describe outcomes, toxicities, and treatment selection discontinuation. A total 141 were included (98% relapsed/refractory). Median age at initiation was 67 years (range 37-91), median prior therapies 3 (0-11), 81% unmutated IGHV, 45% del(17p), 26.8% complex...
The diagnosis of monoclonal B-cell lymphocytosis (MBL) is used to characterize patients with a circulating population clonal B cells, total count less than 5 x 10(9)/L, and no other features lymphoproliferative disorder including lymphadenopathy/organomegaly. natural history clinically identified MBL unclear. goal this study was explore the outcome relative that individuals Rai stage 0 chronic lymphocytic leukemia (CLL).We hematopathology records identify cohort 631 newly diagnosed or CLL....
Summary Although a diagnosis of chronic lymphocytic leukemia (CLL) can have profound effect on the quality life (QOL), few studies objectively measured QOL CLL patients or compared it to general population. We conducted an international, web‐based survey with using standardized instruments published population norms evaluate fatigue and QOL. Co‐morbid health conditions were assessed Charlson Co‐Morbidity Index. Between June October 2006, 1482 responded survey. The physical, social/family,...
A study was undertaken to analyze the survival of chronic lymphocytic leukemia (CLL) patients relative age-matched individuals in general population and determine age-stratified utility prognostic testing.All 2487 diagnosed with CLL between January 1995 June 2008 cared for Mayo Clinic Division Hematology were categorized by age at diagnosis evaluated differences clinical characteristics, time first treatment, overall (OS).Among Rai stage 0 patients, shorter than aged <55 years (P < .001), 55...
The development of cytopenia in chronic lymphocytic leukaemia (CLL) patients can predict poor prognosis. All CLL seen the Division Hematology at Mayo Clinic Rochester from 1 January 1995 to 31 December 2004 (n = 1750) were evaluated for cytopenia, aetiology and clinical outcome. Cytopenia occurred 423 (24.2%) was attributable 303 (17.3%) cases, with 228 (75%) these having bone marrow (BM) failure 75 (25%) autoimmune disease (AID). Survival onset significantly better AID (median 9.1 years)...
Rituximab improves the outcome of patients with non-Hodgkin lymphoma, but does not completely eradicate residual B-cell populations in microenvironment bone marrow and lymph nodes. Adhesion to stromal cells can protect B-cells from apoptosis induced by chemotherapy drugs [(cell adhesion-mediated drug resistance (CAM-DR)]. A similar mechanism rituximab has not, our knowledge, been described. We tested hypothesis that protects malignant rituximab-induced apoptosis, blocking these interactions...
Patients with recurrent/refractory chronic lymphocytic leukemia/small lymphoma (CLL) often have chemotherapy-resistant disease, resulting in poor prognosis. The aim of this study was to learn if inhibition the mammalian target rapamycin (mTOR) would produce tumor responses.This a phase 2 oral single-agent everolimus (10 mg/day) for indolent lymphoid malignancies including CLL.Four 22 patients CLL (18%; 95% confidence interval, 5%-40%) achieved partial remission therapy. An unanticipated...
CpG oligonucleotide 7909 (CpG 7909, PF-03512676), a synthetic 24mer single stranded agonist of TLR9 expressed by B cells and plasmacytoid dendritic cells, is immunomodulatory can cause activation-induced death chronic lymphocytic leukemia (CLL) cells. We report phase I study in 41 patients with early relapsed CLL. A intravenous dose was well tolerated no clinical effects significant toxicity up to 1.05 mg/kg. Single subcutaneous had maximum (MTD) 0.45 mg/kg limiting myalgia constitutional...